Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Becker SW, Kahn D, Rothman S. Cutaneous manifestations of internal malignant tumors. Arch Dermatol Syphilol 1942;45:1069–1080.
McGavran MH, Unger RH, Recant L, Polk HC, Kilo C, Levin ME. A glucagon-secreting alpha cell carcinoma of the pancreas. N Engl J Med 1966;274:1408–1413.
Mallinson GN, Bloom SR, Warin AP, Salmon PR, Cox B. A glucagonoma syndrome. Lancet 1974;2:1–5.
Sabel MS, Prinz RA. Glucagonoma. Surg Dis Pancreas 1998;79:745–756.
Van Heerden FA, Thompson GB. Islet cell tumours of the pancreas. Surg Pancreas 1993;49:545–561.
Joyce CD, Prinz RA. The glucagonoma syndrome. Probl Gen Surg 1994;11:1–16.
Howard JH, Stabile BE, Zinner MJ, Chang S, Belur BS, Passero E. Anatomic distribution of pancreatic endocrine tumors. Am J Surg 1990;159:258–264.
Prinz RA, Badrinath K, Banerji M, Sparagana M, Dorsch TR, Lawrence AM. Operative and chemotherapeutic management of malignant glucagons-producing tumors. Surgery 1981;90:713–719.
Bloom SR, Polak JM. Glucagonoma syndrome. Am J Med 1987;82(suppl):25–36.
Fujita J, Seino Y, Ishida H, et al. A functional study of a case of glucagonoma exhibiting typical glucagonoma syndrome. Cancer 1986;57:860–865.
Norton JA, Hahn CR, Schiebinger R, et al. Amino acid deficiency and the skin rash associated with glucagonoma. Ann Intern Med 1979;91:213–215.
Naets JP, Guns M. Inhibitory effect of glucagon on erythropoiesis. Blood 1980;55:997–1002.
Wawrukiewicz AS, Rosch J, Keller FS, Lieberman DA. Glucagonoma and its angiographic diagnosis. Cardiovasc Intervent Radiol 1982;5:318–324.
Cho KJ, Wilcox CW, Reuter SR. Glucagon producing islet cell tumor of the pancreas. AJR Am J Roentgenol 1977;145:509–516.
Ingemansson S, Holst J, Larsson LI, et al. Localization of glucagonomas by catheterization of the pancreatic veins and with glucagon assay. Surg Gynecol Obstet 1977;145:509–516.
Rosch T, Lightdale CJ, Botet JF. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992;326:1721–1726.
Krenning EP, Kwekkeboom DJ, Oei HY, et al. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. Ann NY Acad Sci 1994;773:416–424.
Bilchik AJ, Sarantou T, Foshag L, Giuliano AE, Ramming KP. Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 1997;122:1040–1048.
Modlin JM, Lewis JJ, Ahlman H, Bilchik AJ, Jumar RR. Management of unresectable malignant endocrine tumors of the pancreas. Surg Gynecol Obstet 1993;176:507–518.
Moertel CG. An Odyssey in the land of small tumors. J Clin Oncol 1987;5:1503–1522.
Altimari AF, Bhoopalam N, Prinz RA, et al. Use of a somatostatin analog (SMS201-995) in the glucagonoma syndrome. Surgery 1986;100:989–996.
Carrasco D, Jackson NA, Samaan R, et al. The carcinoid syndrome: palliation by hepatic arterial embolization. Am J Radiol 1986;147:149–154.
Hajarizadeh H, Ivancev K, Mueller CR, et al. Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate. Am J Surg 1992;163:479–483.
Perry JL, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994;116:1116–1117.
Urszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors: a prospective phase II study in 24 patients. Cancer 1993;71:2624–2630.
Jockenhovel F, Lederbogen S, Olbricht T, et al. The long-acting somatostatin analogue octreotide alleviates symptoms by reducing post-translational conversion of preproglucagon to glucagon in a patient with malignant glucagonoma, but does not prevent tumor growth. Clin Invest 1994;72:127–133.
Moertel C, Hauley J, Johnson L. Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet cell carcinoma. N Engl J Med 1980;303:1189–1194.
Broder LE, Carter SK. Pancreatic islet cell carcinoma: results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973;79:101–107.
Kessinger A, Floley JF, Lemon HM. Therapy of malignant APUD cell tumors: effectiveness of DTIC. Cancer 1983;51:790–794.
Jones DV Jr, Samaan NA, Sellin RV, et al. Metastatic glucagonoma: clinical response to a combination of 5-FU and alpha-interferon. Am J Med 1992;93:348–349.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag New York, Inc.
About this chapter
Cite this chapter
Talamonti, M.S. (2003). Glucagonoma. In: Saclarides, T.J., Millikan, K.W., Godellas, C.V. (eds) Surgical Oncology. Springer, New York, NY. https://doi.org/10.1007/0-387-21701-0_15
Download citation
DOI: https://doi.org/10.1007/0-387-21701-0_15
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-95201-7
Online ISBN: 978-0-387-21701-7
eBook Packages: Springer Book Archive